[Rational basis of polarizing treatment in myocardial infarct].
D000255:Adenosine Triphosphate / Q000096:biosynthesis; D000818:Animals; D002712:Chlorides / Q000627:therapeutic use; D002952:Citric Acid Cycle; D005947:Glucose / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D007511:Ischemia / Q000378:metabolism; D008564:Membrane Potentials; D008928:Mitochondria / Q000378:metabolism; D009203:Myocardial Infarction / Q000378:metabolism* / Q000628:therapy*; D009206:Myocardium / Q000378:metabolism; D009336:Necrosis / Q000378:metabolism; D010085:Oxidative Phosphorylation; D011188:Potassium / Q000627:therapeutic use; D014882:Water-Electrolyte Balance
D002712:Chlorides; D007328:Insulin; D000255:Adenosine Triphosphate; D005947:Glucose; D011188:Potassium
La bases racionales del tratamiento polarizante en el infarto del miocardio.